Business Model & Revenue
COMPASS is a late-stage biotech with a single near-term asset: COMP360, synthetic psilocybin administered with psychological support in clinics, targeting treatment-resistant depression — patients who fail at least two antidepressant courses. The model is regulatory-then-commercial: complete the rolling NDA (final module within two weeks), potentially compress review via the National Priority Voucher, secure DEA rescheduling under the White House executive order, then launch in H1 2027 through the more than 8,500 U.S. treatment centers already equipped to deliver multi-hour monitored sessions.
Economics look like a specialty launch, not chronic-care pharma: a few treatments per year at specialty pricing, sold through a direct commercial team now being selected, with reimbursement, provider training and patient-support infrastructure funded by the current $33.0 million-per-quarter SG&A ramp. A registration-enabling PTSD trial and a VA collaboration on a TRD/PTSD trial in veterans extend the same compound into a second indication — and the only marketed TRD adjunct has captured under 3% of the addressable population, leaving the infrastructure and the market substantially unbuilt.
Financial Highlights
Q3 2026 Results (Quarter Ended September 30, 2026)
| Metric | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| R&D expense | $23.5M | $27.3M | -14% |
| SG&A expense | $33.0M | $13.2M | +150% (launch build) |
| Net loss | $(9.8)M | $(137.7)M | Improved |
| Diluted EPS | $(0.31) | $(1.44) | Beat consensus by $0.10 |
| Warrant fair-value gain | +$40.8M | $(101.3)M loss | Non-cash swing |
Nine Months 2026
| Metric | 9M 2026 | 9M 2025 |
|---|---|---|
| Net loss | $(172.4)M | $(194.0)M |
| EPS (basic and diluted) | $(1.35) | $(2.09) |
| R&D expense | $79.1M | $88.5M |
| SG&A expense | $72.6M | $44.6M |
Balance Sheet Snapshot
| Item | Amount |
|---|---|
| Cash and equivalents (9/30/26) | $444.0M |
| Debt (9/30/26) | $51.0M |
| Shares outstanding (implied) | ≈128M |
| Market cap at $9.23 | ≈$1.16B |
Guidance: current cash expected to fund operating expenses and capital requirements into 2028 — beyond the targeted H1 2027 launch, subject to FDA approval. No revenue guidance; COMP360 is pre-approval. R&D is declining post-Phase 3 completion while SG&A rises for commercial readiness, sales-team selection, provider training, reimbursement and supply-chain buildout.
Competitive Landscape
COMPASS occupies the leading position in FDA-track psychedelic medicine: the only company with two positive Phase 3 trials in TRD and a nearly complete NDA for a synthetic, standardized-dose psilocybin. The commercial frame of reference is sparse — which is both the opportunity and the competitive wildcard.
- Usona Institute (nonprofit): the proximate threat — reportedly completed its FDA application for psilocybin in major depression, and the November 2 headlines around it knocked 27% off CMPS. Nonprofit, naturalistic-dose positioning; a real approval race but a thinner commercial apparatus.
- Johnson & Johnson (JNJ) — Spravato (esketamine): the only approved adjunct for TRD, and the proof the market is underserved: under 3% share of the estimated 4 million U.S. patients, burdened by REMS-style monitoring logistics COMP360 expects to match or beat on durability.
- atai Life Sciences (ATAI): diversified psychedelic platform with its own programs and stakes across the space; earlier-stage in TRD but capital-patient.
- Cybin (CYBN): next-generation psilocybin analogs (deuterated, IV) in mid-stage trials; years behind COMP360's registrational data.
- Mind Medicine (MNMD): broad psychedelic pipeline including an LSD program in GAD; also pre-registration in TRD.
Moats: (1) the registrational dataset itself — two positive Phase 3s, 1,000+ participants, 52-week durability data competitors will need years to replicate; (2) IP and manufacturing around synthetic, GMP psilocybin at standardized 25 mg dosing; (3) regulatory first-mover position including the National Priority Voucher and executive-order tailwinds; (4) a launch-ready commercial organization being assembled ahead of any rival's approval.
Catalysts
- Final NDA module filing within two weeks — the definitive submission event; confirmation starts the formal approval clock, with the National Priority Voucher potentially shortening FDA review to 1–2 months.
- FDA decision and DEA rescheduling: an approval plus timely rescheduling under the White House executive order sets up the H1 2027 launch — the binary that dominates the next twelve months.
- Launch execution signals in 2027: sales-team buildout completion, pricing disclosure, reimbursement coverage progress and early treatment-center activation across the 8,500+ site infrastructure.
- Registration-enabling PTSD Phase 3 trial progression — a second indication expands the TAM materially and de-risks the single-asset profile.
- VA collaboration trial in veterans with TRD and concurrent PTSD — public-sector adoption would be both revenue and validation, with read-through to payer coverage.
Key Risks
- FDA review risk: the NDA is not yet fully filed — the final module submits within two weeks — and approval is not guaranteed; any clinical-site inspection findings, data requests or a CRL would crater a stock whose entire value rests on COMP360 approval.
- Competitive risk: Usona Institute reportedly completed its own FDA application for psilocybin, triggering the 27% November 2 selloff; a rival approval before or near COMP360's launch erodes first-mover pricing and share in a market where the only marketed medicine has captured under 3% of patients.
- Commercial-adoption risk: SG&A tripled YoY to $33.0 million building a launch that assumes COMP360 fits into 8,500+ existing treatment centers; clinic capacity, therapist staffing, reimbursement coding and per-treatment pricing near Spravato levels are unproven assumptions.
- Cash burn and financing risk: guidance funds operations only 'into 2028' — roughly one year past the expected H1 2027 launch — with $51.0 million of debt already drawn; a delayed or slow launch invites dilutive raises from the roughly 128 million shares outstanding base.
- Policy and rescheduling risk: rapid DEA rescheduling depends on a White House executive order and National Priority Voucher mechanics that remain untested for psychedelics; scheduling friction, state-level restrictions or a change in political winds could stall the launch timeline.
Our Thesis
Monday's 27% flush was about competition, and competition is the wrong variable to price first: Usona's program is a naturalistic-dose comparator without COMPASS's registrational package — two positive Phase 3 trials (COMP005, COMP006), more than 1,000 participants dosed, rapid onset with durability extended to one year by an additional 25 mg dose, and a generally well-tolerated profile. The right variables are filing and review mechanics: the rolling NDA completes within two weeks, the National Priority Voucher could shorten FDA review to 1–2 months, and a White House executive order directs DEA to move quickly on rescheduling — an unprecedented regulatory tailwind pointing at a potential H1 2027 launch into 8,500+ existing treatment centers.
At $9.23 the market capitalization is roughly $1.16 billion; net of $444.0 million cash and $51.0 million debt, EV is about $770 million for a company calling COMP360 a blockbuster opportunity in a 4-million-patient market. Our $15.00 target is probability-weighted: 65% at $19 (approval and on-time launch — 4x EV on roughly $500M 2028E sales plus cash, ≈$2.4B equity over 128M shares), 20% at $8 (delay or competitive erosion), 15% at $5 (CRL and a raise): 0.65×19 + 0.20×8 + 0.15×5 = $14.70, call it $15.00. Cash funds operations into 2028, past launch.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.